Australia markets close in 4 hours 50 minutes

Grifols, S.A. (GIFLF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
9.65-1.03 (-9.64%)
At close: 09:32AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.68
Open9.65
Bid9.44 x 38800
Ask9.85 x 42300
Day's range9.65 - 9.65
52-week range7.46 - 15.80
Volume110
Avg. volume264
Market cap5.664B
Beta (5Y monthly)0.67
PE ratio (TTM)96.50
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date03 June 2021
1y target estN/A
  • GlobeNewswire

    Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group

    With today’s announcement of the transaction completion, Grifols and Haier Group will work together through Shanghai RAAS (SRAAS) to drive synergies that enhance China’s healthcare systemThrough a share purchase agreement Grifols has sold a 20% equity stake in SRAAS to Haier Group for RMB 12.5 billion (approximately EUR 1.6 billion)Grifols and SRAAS extend their exclusive albumin distribution agreement over the next 10 years, and SRAAS has the option to prolong it through 2044Grifols will use al

  • GlobeNewswire

    Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies

    With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to meet strong demand Yimmugo, already approved for production and marketing in Europe, is the first U.S.-approved medicine in Biotest’s portfolio and is manufactured with an innovative process at Biotest’s new FDA-certified ‘Next Level’ facility U.S. approval of Yimmugo paves the way for other Biotest proteins in late-stage development, including fibrinogen and trimodulin Lau

  • PR Newswire

    Grifols 2023 Annual Report on Form 20-F filed with the SEC

    Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission ("SEC").